Complement activation in vitro by the red cell substitute, liposome- encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1

Transfusion

Volumn 37, Issue 2, 1997, Pages 150-159

  Szebeni, J ^a   Wassef, N M ^a   Hartman, K R ^a   Rudolph, A S ^b   Alving, C R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A [DEARGININE]; EGTAZIC ACID; HEMOGLOBIN; LIPOSOME; MAGNESIUM;

ARTICLE; BLOOD SUBSTITUTION; CELL AGGREGATION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE; HUMAN; HUMAN CELL; PHOSPHOLIPID VESICLE;

EID: 0031041766     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1997.37297203517.x     Document Type: Article

References (59)

1. Djordjevich L, Miller IF. Synthetic erythrocytes from lipid encapsulated hemoglobin. Exp Hematol 1980;8:584-92.
2. Farmer MC, Gaber BP. Liposome encapsulated hemoglobin as an artificial oxygen-carrying system. Methods Enzymol 1987;149:184-200.
3. Rabinovici R, Rudolph AS, Ligler FS, et al. Liposome-encapsulated hemoglobin: an oxygen-carrying fluid. Circ Shock 1990;32:1-17.
4. Rabinovici R, Rudolph AS, Feuerstein G. Improved biological properties of synthetic distearoyl phosphatidyl choline-based liposome in the conscious rat. Circ Shock 1990;30:207-19.
5. Rabinovici R, Rudolph AS, Ligler FS, et al. Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. Circ Shock 1992;37:124-33.
6. Rabinovici R, Rudolph AS, Vernick J, Feuerstein G. A new salutary resuscitative fluid: liposome encapsulated hemoglobin/ hypertonic saline solution. J Trauma 1993;35:121-6; discussion 126-7.
7. Rabinovici R, Rudolph AS, Vernick J, Feuerstein G. Lyophilized liposome encapsulated hemoglobin: evaluation of hemodynamic, biochemical, and hematologic responses. Crit Care Med 1994;22:480-5.
8. 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. Proc Natl Acad Sci USA 1991;88:10976-80.
9. Rudolph AS. Encapsulation of hemoglobin in liposomes. In: Winslow RM, Vandegriff KD, Intaglietta M, eds. Blood substitutes: physiological basis of efficacy. Boston: Birkhauser, 1995:98-104.
10. Rabinovici R, Rudolph AS, Feuerstein G. Characterization of hemodynamic, hematologic, and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ Shock 1989;29:115-32.
11. Rabinovici R, Rudolph AS, Yue TL, Feuerstein G. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. Circ Shock 1990;31:431-45.
12. Szebeni J, Wassef NM, Spielberg H, et al. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Commun 1994;205:255-63.
13. Szebeni J, Wassef NM, Rudolph AS, Alving CR. Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. Artif Cells Blood Substit Immobil Biotechnol 1995;23:355-63.
14. Heideman M, Hugli TE. Anaphylatoxin generation in multisystem organ failure. J Trauma 1984;24:1038-43.
15. Gallinaro R, Cheadle WG, Applegate K, Polk HC Jr. The role of the complement system in trauma and infection. Surg Gynecol Obstet 1992;174:435-40.
16. Moore FD Jr. Therapeutic regulation of the complement system in acute injury states. Adv Immunol 1994;56:267-99.
17. Hammerschmidt DF, Weaver LJ, Hudson LD, et al. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet 1980;1:947-9.
18. Hammerschmidt DE. Activation of complement and granulocytes in shock. In: Whaley K, ed. Complement in health and disease. Boston: MTP Press, 1987:267-87.
19. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1 : in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990:249:146-51.
20. Winslow RM, Chapman KW. Pilot-scale preparation of hemoglobin solutions. Methods Enzymol 1994;231:3-16.
21. Cliff RO, Kwasiborski V, Rudolph AS. A comparative study of the accurate measurement of endotoxin in liposome-encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 1995;23:331-6.
22. Wright DG. Human neutrophil degranulation. Methods Enzymol 1988;162:538-51.
23. Craddock PR, Hammerschmidt D, White JG, et al. Complement (C5a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 1977;60:260-4.
24. Cheung AK. The complement system in extracorporeal circulation. Plasma Ther Transfus Technol 1984;5:505-16.
25. Labarre D, Montdargent B, Carreno MP, Maillet F. Strategy for in vitro evaluation of the interactions between biomaterials and complement system. J Appl Biomater 1993;4:231-40.
26. Chang TM, Lister CW. Assessment of blood substitutes: II. Invitro complement activation of human plasma and blood for safety studies in research, development, industrial production and preclinical analysis. Artif Cells Blood Substit Immobil Biotechnol 1994;22:171-80.
27. Szebeni J, Hauser H, Eskelson CD, et al. Interaction of hemoglobin derivatives with liposomes. Membrane cholesterol protects against the changes of hemoglobin. Biochemistry 1988;27:6425-34.
28. Mold C, Rodgers CP, Richards RL, et al. Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. J Immunol 1981;126:856-60.
29. Kovacsovics T, Tschopp J, Kress A, Isliker H. Antibody-independent activation of Cl, the first component of complement, by cardiolipin. J Immunol 1985;135:2695-700.
30. Okada N, Yasuda T, Okada H. Antibody-mediated alternative pathway activation resists inhibition by sialoglycolipids. J Immunol 1985;134:3316-9.
31. Comis A, Easterbrook-Smith SB. Inhibition of serum complement haemolytic activity by lipid vesicles containing phosphatidylserine. FEBS Lett 1986;197:321-7.
32. Michalek MT, Bremer EG, Mold C. Effect of gangliosides on the activation of the alternative pathway of human complement. J Immunol 1988;140:1581-7.
33. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991;146:4234-41.
34. Funato K, Yoda R, Kiwada H. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim Biophys Acta 1992;1103:198-204.
35. Wassef NM, Johnson SH, Graeber GM, et al. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J Immunol 1989;143:2990-5.
36. Hugli TE. Structure and function of the anaphylatoxins. Springer Semin Immunopathol 1984;7:193-219.
37. Marceau F, Lundberg C, Hugli TE. Effects of the anaphylatoxins on circulation. Immunopharmacology 1987;14:67-84.
38. Liu D, Liu F, Song YK. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. Biochim Biophys Acta 1995;1235:140-6.
39. Alving CR, Swartz GM Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit Rev Immunol 1991;10:441-53.
40. Moore FD Jr, Austen KF, Fearon DT. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J Immunol 1982;128:1302-6.
41. Fries LF, Gaither TA, Hammer CH, Frank MM. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 1984;160:1640-55.
42. Wassef NM, Swartz GM, Herman JD, et al. Toxic effects of antileishmanial reverse-phase evaporation liposomes containing dicetyl phosphate in monkeys. Drug Delivery 1995;2:181-9.
43. Salama A, Hugo F, Heinrich D, et al. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 1988;318:408-14.
44. Kubatiev A, Rudko I, Ermolenko V. Complement activation and neutrophil aggregation changes during haemodialysis. Int J Clin Pharmacol Res 1993;13:293-9.
45. Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis. Artif Organs 1994;18:880-7.
46. Skroeder NR, Kjellstrand P, Holmquist B, et al. Individual differences in biocompatibility responses to hemodialysis. Int J Artif Organs 1994;17:521-30.
47. Skroeder NR, Kjellstrand P, Holmquist B, et al. On complement net generation in fast hemodialysis: are high blood flow rates bioincompatible? Am J Kidney Dis 1995;25:896-903.
48. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
49. Barenholz Y, Amselem S. Quality control assays in the development and clinical use of liposome-based formulations. In: Gregoriadis G, ed. Liposome technology. 2nd ed. Boca Raton: CRC Press, 1993:527-616.
50. Coune A, Sculier JP, Fruhling J, et al. Iv administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man. Cancer Treat Rep 1983;67:1031-3.
51. Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114:664-6.
52. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-85.
53. Gibb AL, Freeman AM, Smith RA, et al. The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4. Biochim Biophys Acta 1993;1180:313-20.
54. Cheung AK, Parker CJ, Hohnholt M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 1994;46:1680-7.
55. Gillinov AM, DeValeria PA, Winkelstein JA, et al. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 1993;55:619-24.
56. Homeister JW, Satoh PS, Kilgore KS, Lucchesi BR. Soluble complement receptor type 1 prevents human complementmediated damage of the rabbit isolated heart. J Immunol 1993;150:1055-64.
57. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994;57:363-70.
58. Chavez-Cartaya RE, DeSola GP, Wright L, et al. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. Transplantation 1995;59:1047-52.
59. Szebeni J, Wassef MN, Rudolph AS, Alving CR. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim Biophys Acta 1996;1285:127-30.